Saffron 30 mg

by Exir USA · tablet or pill · 60 tablets

  • On the market (NIH)
  • DSLD label 214278
  • Serving 1 tablet
  • 60 servings

Saffron 30 mg by Exir USA lists 2 ingredients, 2 with an amount per serving of 1 tablet, such as 15 mg of saffron and 15 mg of saffron extract. Its current label entered the NIH Dietary Supplement Label Database on March 24, 2020.

What is in Saffron 30 mg?

Each row as the label prints it, per serving of 1 tablet. The capsule beside an amount places it among every product in the NIH database that lists the same ingredient: the bar is the middle half of their amounts, the line in it the median, the whiskers the 10th and 90th percentiles; the green tick is the FDA Daily Value and the red dashed tick the adult upper limit (IOM).

Saffron 30 mg: Supplement Facts rows against the market (DSLD label 214278, January 2026 release)
IngredientAmount% DVAmong products listing it
Saffron15 mgSaffron in Saffron 30 mg against 201 products30 mg per serving; the middle half of products list 20 mg to 88.5 mg, the median 30 mg.30 mg

37% of 201 products listing saffron give more (median 30 mg). Per day at the most servings: 90 mg.

Saffron extractas Crocin, Crocus sativus L. stigma powder, SafranalSaffron extract (Form: Crocus sativus L. stigma powder PlantPart: stigma Genus: Crocus Species: sativus Classifier: L., combined Crocin Note: 15%, Safranal Note: 8%)15 mg

Source: NIH ODS Dietary Supplement Label Database, label 214278 (entered March 24, 2020), version 9.4.0. See the label on DSLD. Amounts are what the maker printed; DSLD does not test products. Daily Values: the FDA's Daily Value page.

Is that a lot?

Every amount on this label with a position sits within the middle 80% of the products that list the same ingredient.

The NIH database records 2 to 3 servings a day from the label's directions; its % Daily Values are for adults and children 4 or more years of age. The directions as printed are further down this page.

The Tolerable Upper Intake Level is the most of a nutrient per day, from food, water and supplements together, that is likely to pose no risk for almost all adults (Institute of Medicine, 2011). It does not apply under medical supervision. This page compares labels; it is not medical advice.

Sources: amounts from the DSLD label; Daily Values from 21 CFR 101.9(c)(8)(iv); adult upper limits from the Institute of Medicine's DRI summary tables (2011). How positions are computed.

Which products have the closest formulas?

6 products list the very same ingredients; the nearest amounts come first.

Source: ingredient lists of every product's current label in DSLD (version 9.4.0); similarity weights each shared ingredient by how rare it is.

What does the label say about taking it?

Quoted from the label as DSLD transcribed it: the maker's words, including any claim about what the product does, which the FDA has not evaluated and PlainVitamins does not endorse.

Directions
Recommendation: 1 Tablet 2-3 times daily
Allergens and what it does not contain
Allergen Free
Made with NO GMO Ingredients
Artificial Excipient Free
No artificial coloring or preservatives.
Storage
Keep tightly closed in a cool, dry, place.

Source: label statements in DSLD label 214278.

What else is on the label?

Other ingredients: Vegetable Cellulose, Rice Extract Blend, Rice Bran.

Seals and symbols as the label prints them (the maker's; a certifier's own list confirms a seal): GMP Good Manufacturing Practice Consistent Quality.

How many labels does Saffron 30 mg have?

3 labels are on file under this name since March 24, 2020: other sizes, label designs and reformulations. The current one leads this page.

  1. Label 214278 (current) Entered March 24, 2020 · on the market · 60 tablets
  2. Label 214275 Entered March 24, 2020 · on the market · 180 tablets
  3. Label 214271 Entered March 24, 2020 · on the market · 120 tablets

Source: DSLD label entry and market events, version 9.4.0 (labels entered through September 25, 2025).

Who makes it?

The label names Epicure Garden (distributor). All Exir USA products.

Where next?